JP2023547475A5 - - Google Patents
Info
- Publication number
- JP2023547475A5 JP2023547475A5 JP2023526313A JP2023526313A JP2023547475A5 JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5 JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023526313 A JP2023526313 A JP 2023526313A JP 2023547475 A5 JP2023547475 A5 JP 2023547475A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- alkoxy
- alkyl
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107853P | 2020-10-30 | 2020-10-30 | |
| US63/107,853 | 2020-10-30 | ||
| PCT/IB2021/060043 WO2022091028A1 (en) | 2020-10-30 | 2021-10-29 | Methods for improving renal function with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023547475A JP2023547475A (ja) | 2023-11-10 |
| JP2023547475A5 true JP2023547475A5 (https=) | 2024-10-24 |
Family
ID=81382005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526313A Pending JP2023547475A (ja) | 2020-10-30 | 2021-10-29 | Ｂｅｔブロモドメイン阻害剤及びナトリウム依存性グルコース輸送体２阻害剤の組み合わせを用いて腎機能を改善するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230381178A1 (https=) |
| EP (1) | EP4236955A4 (https=) |
| JP (1) | JP2023547475A (https=) |
| KR (1) | KR20230098275A (https=) |
| CN (1) | CN116390721A (https=) |
| AU (1) | AU2021368618B2 (https=) |
| CA (1) | CA3197706A1 (https=) |
| IL (1) | IL301831A (https=) |
| MX (1) | MX2023004671A (https=) |
| TW (1) | TW202233194A (https=) |
| WO (1) | WO2022091028A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650824A (zh) | 2019-11-05 | 2022-06-21 | 雷斯韦洛吉克斯公司 | 用bet溴结构域抑制剂和钠依赖性葡萄糖转运蛋白2抑制剂的组合治疗和/或预防主要不良心血管事件(mace)的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4678242A3 (en) * | 2013-04-18 | 2026-03-18 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| AU2015210898A1 (en) * | 2014-01-31 | 2016-07-28 | Janssen Pharmaceutica Nv | Methods for the treatment and prevention of renal disorders and fatty liver disorders |
| US10111885B2 (en) * | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
-
2021
- 2021-10-29 CA CA3197706A patent/CA3197706A1/en active Pending
- 2021-10-29 WO PCT/IB2021/060043 patent/WO2022091028A1/en not_active Ceased
- 2021-10-29 US US18/032,450 patent/US20230381178A1/en active Pending
- 2021-10-29 JP JP2023526313A patent/JP2023547475A/ja active Pending
- 2021-10-29 AU AU2021368618A patent/AU2021368618B2/en active Active
- 2021-10-29 MX MX2023004671A patent/MX2023004671A/es unknown
- 2021-10-29 EP EP21885492.5A patent/EP4236955A4/en active Pending
- 2021-10-29 CN CN202180072395.4A patent/CN116390721A/zh active Pending
- 2021-10-29 TW TW110140217A patent/TW202233194A/zh unknown
- 2021-10-29 IL IL301831A patent/IL301831A/en unknown
- 2021-10-29 KR KR1020237018039A patent/KR20230098275A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006523216A5 (https=) | ||
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| JP2022541503A (ja) | Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置 | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| JP2006518731A5 (https=) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2023526567A5 (https=) | ||
| US8673930B2 (en) | Pyrimidylaminobenzamide derivatives for systemic mastocytosis | |
| JP2023547475A5 (https=) | ||
| JP2023500685A5 (https=) | ||
| US12478614B2 (en) | Inhibitors of glutathione s-transferases (GSTs) and NAD(P)H:quinone oxidoreductase 1 (NQO1), pharmaceutical compositions, and uses in managing cancer | |
| CN115397415A (zh) | 乳腺癌治疗剂 | |
| US20240277722A1 (en) | Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent | |
| AU2002309211B2 (en) | Treatment of renal fibrosis | |
| JP2023549703A5 (https=) | ||
| JP2022542663A (ja) | Ｓｇｌｔ阻害剤、例えばｓｇｌｔ１／２阻害剤を含む治療 | |
| JP2009506043A5 (https=) | ||
| JP2022502378A5 (https=) | ||
| EP3957310B1 (en) | Composition comprising sotagliflozin and a tyrosine kinase activity inhibitor for use in the treatment of cancer | |
| JP7571024B2 (ja) | 抗ｃｃｒ４抗体抵抗性のがんの治療剤 | |
| AU2002309211A1 (en) | Treatment of renal fibrosis | |
| JP2021534208A (ja) | 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 | |
| JP2023509186A5 (https=) | ||
| US20110281813A1 (en) | Method of treating c-kit positive relapsed acute myeloid leukemia | |
| JP2022543803A (ja) | （６ａＳ）－６－メチル－５，６，６ａ，７－テトラヒドロ－４Ｈ－ジベンゾ［ｄｅ，ｇ］キノリン－１０，１１－ジオールの医薬組成物 |